Navitus Health Solutions’ Post

The noise around GLP-1s and their potential impact on the MedTech sector is intensifying. In this new blog, IQVIA MedTech discusses the importance of having the right data and analytics in place to cut through the generalizations - allowing you to reveal the complete picture for your business. Read now. Authors: Chris Ludwig and Michelle Edwards https://bit.ly/46HtNCO #GLP1 #MedTech

NEW INSIGHTS: GLP-1 and Impact on Medtech sector... through the lens of Real-World Evidence & Data! #medtech companies are already considering how best to articulate the continued value of their products – to audiences including #regulators, #physicians, #payers, and #analysts. A crucial step is to understand the company’s target patient populations through the lens of #glp1 use. Thanks Chris Ludwig and Michelle Edwards for sharing these insights. Francois Laflamme Joe Franco, MBA Chris Hankey Andrew Al Tork Sabrina S. Charles #medtech #medicaldevices #bariatricsurgery #cardiovascular #sleepapnea #diabetes #stroke #realworldevidence #patientoutcomes #clinicalpractice #surgicalprocedures #weareiqvia

Understanding the impact of #GLP1 on your #MedTech business is of crucial importance - both to anticipate what's next and to answer questions from your investors. This is an area where IQVIA MedTech can help!

GLP-1 drugs, that help with weight loss, have been on the market for many years, but recent trials are being designed with endpoints that have a direct impact on medical devices (ex: Dialysis, CPAP machines). But, what is the real risk for the MedTech companies? Learn more about it in this article from IQVIA #medtech #iqvia

The noise around GLP-1s and their potential impact on the MedTech sector is intensifying. In this new blog, IQVIA MedTech discusses the importance of having the right data and analytics in place to cut through the generalizations - allowing you to reveal the complete picture for your business. Read now. Authors: Chris Ludwig and Michelle Edwards https://bit.ly/3HIXkSV #GLP1 #MedTech

State Drug Price Transparency Reporting is increasing in complexity and more states are requiring reporting. We are excited to simplify the process. Contact me to see how.

Using a decentralized approach to #clinicaltrials can improve data quality, enhance the patient experience, and reduce the time it takes to get new drugs to market. Learn how. https://lnkd.in/eseX98zF

Using a decentralized approach to #clinicaltrials can improve data quality, enhance the patient experience, and reduce the time it takes to get new drugs to market. Learn how. https://lnkd.in/g9NDG5nq

Recently the FDA released important recommendations on leveraging Real-World Data (RWD) into Real-World Evidence (RWE).  Explore the draft guidance here: https://lnkd.in/gmJgvk_D I found the key points to be around: ◼ The importance of collecting high-quality data ◼ Robust data management and analysis to generate evidence ◼ Clear study design   Curious to see how these guidelines reshape study design in 2024! #FDAInsights #RealWorldEvidence #ClinicalResearch

BIG NEWS! The Biden administration moved Tuesday to reclassify marijuana as a lower-risk substance, a historic move that acknowledges the medical benefits of the long-criminalized drug and carries broad implications for cannabis-related research and the industry at large. This shift could have a significant impact on 280E and the broader landscape of cannabis-related research. The formal rulemaking process is lengthy, typically includes a public comment period and could take months to complete. Read more here: https://cnn.it/3y0AQuO